|
Market Closed -
Japan Exchange
02:30:00 2026-09-15 EDT
|
5-day change | 1st Jan Change | ||
| 6,500.00 JPY | +1.34% |
|
-0.98% | -21.15% |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 08-17 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 10,553B 68.27B 59.16B 55.83B 50.64B 95B 6,543B 95.69B 667B 257B 3,319B 256B 251B | P/E 2026 * |
20.8x | P/E 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise Value | 9,643B 62.38B 54.05B 51.01B 46.28B 86.81B 5,979B 87.44B 609B 235B 3,033B 234B 229B | EV / Sales 2026 * |
6.95x | EV / Sales 2027 * | 6.15x |
| Free-Float |
38.12% | Yield 2026 * |
2.12% | Yield 2027 * | 2.42% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4519 | Delayed | |
OTC Markets
| CHGCF | Delayed | |
|
Mexican S.E.
| 4519 N | End-of-day quote | |
|
Tradegate
| CUP | Real-time | |
|
Deutsche Boerse AG
| CUP | Delayed | |
|
Börse Stuttgart
| CUP | Delayed | |
|
Boerse Muenchen
| CUP | Real-time |
Last Transcript: Chugai Pharmaceutical Co., Ltd.
| 1 day | +1.34% | ||
| 1 week | -0.98% | ||
| Current month | -5.97% | ||
| 1 month | -6.25% | ||
| 3 months | -12.75% | ||
| 6 months | -30.57% | ||
| Current year | -21.15% |
| 1 week | 6,293 |  | 6,579 |
| 1 month | 6,293 | | 7,141 |
| Current year | 6,293 | | 10,700 |
| 1 year | 6,250 | | 10,700 |
| 3 years | 4,197 | | 10,700 |
| 5 years | 3,191 | | 10,700 |
| 10 years | 1,003.33 | | 10,700 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 2021-02-28 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 2024-03-27 |
Kazuhiko Nishi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
BRD | Director/Board Member | 63 | 2020-02-29 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 2024-03-27 |
| Director/Board Member | 51 | 2025-02-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.34% | -0.98% | -2.97% | +45.25% | 68.27B | |
| +0.71% | +1.76% | +52.87% | +98.68% | 1,015B | |
| -0.66% | -2.04% | +48.61% | +63.30% | 642B | |
| +0.54% | +5.21% | +20.28% | +72.06% | 463B | |
| -0.40% | +2.62% | +38.13% | +37.63% | 353B | |
| -0.32% | +1.54% | +16.24% | +23.04% | 265B | |
| -0.75% | +1.68% | +5.80% | +10.38% | 254B | |
| -1.05% | -4.26% | +37.18% | +44.38% | 206B | |
| -1.60% | -5.51% | -22.30% | -58.60% | 191B | |
| -0.04% | -1.40% | +28.47% | +91.07% | 182B | |
| Average | -0.22% | -3.25% | +22.23% | +42.72% | 363.85B | |
| Weighted average by Cap. | -0.08% | -2.21% | +33.48% | +58.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,388B 8.98B 7.78B 7.34B 6.66B 12.5B 861B 12.59B 87.71B 33.8B 437B 33.73B 32.99B | 1,529B 9.89B 8.57B 8.09B 7.34B 13.76B 948B 13.86B 96.59B 37.22B 481B 37.15B 36.33B |
| Net income | 506B 3.28B 2.84B 2.68B 2.43B 4.56B 314B 4.59B 31.99B 12.33B 159B 12.3B 12.03B | 583B 3.77B 3.27B 3.09B 2.8B 5.25B 362B 5.29B 36.86B 14.2B 184B 14.18B 13.86B |
| Net Debt | -910B -5.89B -5.1B -4.81B -4.37B -8.19B -564B -8.25B -57.5B -22.16B -286B -22.11B -21.63B | -1,151B -7.44B -6.45B -6.09B -5.52B -10.36B -714B -10.44B -72.7B -28.02B -362B -27.96B -27.34B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-15 | JP¥6,500.00 | +1.34% | 1,907,400 |
| 26-09-14 | JP¥6,414.00 | -0.12% | 1,755,500 |
| 26-09-11 | JP¥6,422.00 | +0.06% | 3,008,400 |
| 26-09-10 | JP¥6,418.00 | -0.90% | 3,141,500 |
| 26-09-09 | JP¥6,476.00 | -0.86% | 2,871,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
Select your edition
All financial news and data tailored to specific country editions
